Mr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman of the Board of Directors, Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), OvaScience (NASDAQ: OVAS), where he serves as Chairman of the Board and FlexPharma (NASDAQ FLKS). Mr. Aldrich also serves as a Director of Longwood portfolio companies Mitobridge, Inc., Colorescience, Inc. and KalVista Pharmaceuticals. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich also serves on the Board of the Massachusetts Eye & Ear Infirmary. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.
Dr. Dipp is a co-founder and Partner of Longwood Fund. Dr. Dipp currently serves as the CEO and co-founder of OvaScience (NASDAQ: OVAS), a Longwood portfolio company. Dr. Dipp also co-founded Longwood portfolio companies Alnara Pharmaceuticals, Verastem (NASDAQ: VSTM) and FlexPharma (NASDAQ FLKS). Previously, Dr. Dipp was the Senior Vice President and Head of GSK's Centre of Excellence for External Drug Discovery (CEEDD). Prior to leading GSK’s CEEDD, Dr. Dipp was the Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008). Before joining Sirtris, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp holds an MD from Oxford University Medical School and a PhD in Physiology from the University of Oxford. Dr. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, the Beth Israel Deaconess Medical Center Board of Directors, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board.
Dr. Westphal is a co-founder and Partner of Longwood Fund, which founds and invests in medical companies. Dr. Westphal currently serves as the co-founder, CEO and Chairman of Longwood portfolio company FlexPharma (NASDAQ FLKS) and co-founder, former CEO, and Executive Chairman of Longwood portfolio company Verastem (NASDAQ: VSTM). Dr. Westphal also co-founded Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), and OvaScience (NASDAQ: OVAS). In addition, he co-founded Sirtris in 2004 (NASDAQ: SIRT; acquired by GSK), and served as CEO until 2010. Dr. Westphal previously served as co-founder/CEO of Alnylam Pharmaceuticals (NASDAQ: ALNY), Acceleron Pharmaceuticals (NASDAQ: XLRN) and Momenta Pharmaceuticals (NASDAQ: MNTA). Companies founded by Dr. Westphal have invented important drugs, including the largest-selling heparin in the US, and several experimental medicines: for cystic fibrosis (phase 3), for currently incurable cancers (phase 2), and for serious inflammatory disorders (phase 2). In addition, these companies have created substantial shareholder value and aggregate market capitalizations (sustained) of over $12 billion. Dr. Westphal was appointed to the BIO Emerging Companies Section Governing Board and serves on the Board of Fellows of Harvard Medical School, and the Board of Overseers of the Boston Symphony Orchestra. He earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in leading journals such as Cell, Nature and Nature Genetics. Dr. Westphal has been featured in the media, including on ‘60 Minutes', CNN, an ABC News Special hosted by Barbara Walters, and as the subject of a Fortune cover article.
Dr. Donabedian is a Venture Partner of Longwood Fund. He joins from AbbVie, where as Vice President and Head, Ventures and Early Stage Collaborations he led a global team of business development and investment professionals that made minority investments in biotech companies, licensed or acquired preclinical and Phase 1 compounds and created partnerships with leading academic institutions. Prior to Abbvie, Dr. Donabedian was Senior Vice President at Locust Walk Partners a life sciences consulting firm. Previously, Dr. Donabedian was VP Global New Deal Strategy and Development at GlaxoSmithKline (GSK). Prior to that, he held management positions at Surface Logix and Senior Manager and Accenture's Strategic Services Consulting Group. Dr. Donabedian began his career as a research scientist with Dow Chemical and Boston Scientific. He holds a Bachelor of Arts in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and a Masters of Business Administration from the University of North Carolina at Chapel Hill. He currently serves on the Board of Alcyone Life Sciences, a privately held biotech company he co-founded. He is also a strategic advisor to DNATrix.
Mr. Malone is the Chief Financial Officer of Longwood where he has responsibility for all financial and operational aspects of the Funds and the management company. He has over 30 years' experience in financial services worldwide, having worked in Europe and the UK with the last 15 years spent in the Boston, MA. He has an honors degree in science from University College Dublin and is a Fellow of the Irish Institute of Chartered Accountants. Additionally he has postgraduate qualifications in information technology from Dublin City University and in International Financial Reporting Standards.
Brian Malone started his career in Dublin, Ireland with Ernst & Young before moving to Guernsey in the Channel Islands where he worked for KPMG, Barings and Old Mutual. He moved to London to take a role as Chief Financial Officer of Old Mutual's Investment Management business. He was involved with the listing of Old Mutual on the London Stock Exchange (ticker OML).
Ms. Dipp leads Investor Relations at Longwood Fund. Prior to joining Longwood, Ms. Dipp was a Senior Associate heading up Investor Relations at Brazos Private Equity Partners. Prior to Brazos, Margaret was a Private Equity Analyst in the Investor Relations and Fund Placement division of The Blackstone Group. Ms. Dipp received a Bachelor of Arts degree with high honors from Southern Methodist University and a Masters in International Relations from Oxford University.
Chairman of the Board, President and Chief Executive Officer of Charles River Laboratories
Managing Partner and CEO of the Boston Celtics
Peter Hutt, LLB, LLM
Former FDA GC, SAB: Sirtris (NASDAQ: SIRT, now GSK), Alnara, OvaScience (NASDAQ: OVAS), Flex Pharma (NASDAQ: FLKS), BOD: Momenta (NASDAQ: MNTA)
Rod MacKinnon, PhD
Nobel Prize, Co-Founder Flex Pharma (NASDAQ: FLKS), Rockefeller University
John Maraganore, PhD
CEO Alnylam (NASDAQ: ALNY)
Brian McVeigh, CPA, CMA, CLP, MBA
GlaxoSmithKline, Vice President, WWBD Transactions and Investment Management
Chairman and Chief Executive Officer Alkermes (NASDAQ: ALKS), BOD: Sirtris (NASDAQ: SIRT, now GSK)
Paul Schimmel, PhD
NAS, Scripps, Co-Founder Alnylam (NASDAQ: ALNY), Momenta (NASDAQ: MNTA) and Sirtris (NASDAQ: SIRT, now GSK)
Former President Pepsi, Former CEO, Apple, Investor: Flex Pharma (NASDAQ: FLKS)
Phil Sharp, PhD
Nobel Prize, Co-Founder Biogen and Alnylam (NASDAQ: ALNY), NAS, SAB: Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM)
David Sinclair, PhD
Harvard, Co-Founder/SAB Sirtris (NASDAQ: SIRT, now GSK), OvaScience (NASDAQ: OVAS)
Moncef Slaoui, PhD
GlaxoSmithKline, Chairman R&D
Former Chairman, President and CEO Genzyme, BOD: Verastem (NASDAQ: VSTM)
Chris Walsh, PhD
Harvard, NAS, Genzyme, SAB: Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM), Flex Pharma (NASDAQ: FLKS)
SAB = Scientific Advisory Board, BOD = Board of Directors, NAS = National Academy of Sciences